Irritable Bowel Syndrome (IBS) is a common disorder that greatly affects quality of life. Several medications have been approved for use in IBS – both constipation (IBS-C) and diarrhea (IBS-D). The American Gastroenterological Association just released guidelines provide evidence-based recommendations for patients.

The GameChanger 
In the last 10 years several pharmacotherapies have been FDA approved for both constipation IBS-C) and IBS-D. Updated guidelines from the AGA review the literature surrounding these and other therapies for evidenced based guidelines update. For example, secretagogues such as linactolide are now first line treatment after PEG laxatives for IBS-C 

 
Show Segments 
00:00 – Introduction 
01:28 – Irritable Syndrome (IBS) Bowel Background 
04:04 – AGA Evidence-Based Recommendations  
06:33 – IBS-D Recommendations  
14:29 – IBS – D and IBS – C Recommendations 
17:39 – IBS – C Recommendations 
26:54 – Closing Remarks 

Host
Geoff Wall, PharmD, BCPS, FCCP, CGP 
Professor of Pharmacy Practice, Drake University 
Internal Medicine/Critical Care, UnityPoint Health 

 
References and resources:
AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation

 
Redeem your CPE or CME credit

• CPE (Pharmacist)
• CME (Physician)

Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode) 

• Pharmacists: Get a Membership 
• Prescribers: Get a Membership  

 
Continuing Education Information:
Learning Objectives:
1. Discuss the pharmacologic and non-pharmacologic therapies for treatment of Irritable Bowel Syndrome-Constipation
2. Discuss the pharmacologic and non-pharmacologic therapies for treatment of Irritable Bowel Syndrome-Diarrhea


0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-22-282-H01-P
Initial release date: 08/15/22
Expiration date: 08/15/2023
Additional CPE & CME details can be found here

Follow CEimpact on Social Media:
LinkedIn
Instagram